Tracking climate mitigation efforts in 30 major emitters: Economy-wide projections and progress on key sectoral policies

Reducing global greenhouse gas (GHG) emissions to zero is a crucial step to minimise the worst effects of climate change. The growing political consensus on the dangers of climate change and the increasing number of climate policies implemented is a sign for cautious optimism. Countries increasingly recognise the need to achieve net zero emissions globally by mid-century but still need to implement near-term policy actions and measures to ensure this long-term ambition trigger the transformation necessary to meet the collective goals of the Paris Agreement. This report documents near-term climate policies and measures adopted in the 30 major economies and assesses resulting future GHG emissions trajectories up to 2030. The countries analysed jointly account for 80% of total GHG emissions in 2019. Emissions trends remain far from the goals of the Paris Agreement in the period post-2020. Global emissions should fall 7.6% each year up until 2030 to get on track to meet the goals of the Paris Agreement (UNEP, 2019). Our projections show that emissions reductions under current policies remain woefully insufficient. Emissions in the 30 economies as a group are projected to increase on average by approximately 0.4% per year between 2021 and 2030

Predictive value of PET response combined with baseline metabolic tumor volume in peripheral T-cell lymphoma patients

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive non-Hodgkin lymphomas with poor outcomes on current therapy. We investigated whether response assessed with PET/CT combined with baseline total metabolic tumor volume (TMTV) could detect early relapse or refractory disease. Methods: From 7 European centers, 140 patients with nodal PTCL who underwent baseline PET/CT were selected. Forty-three had interim PET (iPET) performed after 2 cycles (iPET2), 95 had iPET performed after 3 or 4 cycles (iPET3/4), and 96 had end-of-treatment PET (eotPET). Baseline TMTV was computed with a 41% SUVmax threshold, and PET response was reported using the Deauville 5-point scale. Results: With a median of 43 mo of follow-up, the 2-y progression-free survival (PFS) and overall survival (OS) were 51% and 67%, respectively. iPET2-positive patients (Deauville score ≥ 4) had a significantly worse outcome than iPET2-negative patients (P 230 cm3 and iPET3/4-negative [59%/84%]; TMTV ≤ 230 cm3 and iPET3/4-positive [42%/50%]; TMTV > 230 cm3 and iPET3/4-positive [0%/18%]). Conclusion: iPET response is predictive of outcome and allows early detection of high-risk PTCL patients. Combining iPET with TMTV improves risk stratification in individual patients

Corrigendum to ‘Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers’

International audienc

Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers

International audienceBackground: Peripheral T-cell lymphoma (PTCL) remains a therapeutic challenge. Due to the rarity and the heterogeneity of PTCL, no consensus has been achieved regarding even the type of first-line treatment. The benefit of autologous stem-cell transplantation (ASCT) is, therefore, still intensely debated.Patients and methods: In the absence of randomized trials addressing the role of ASCT, we performed a large multicentric retrospective study and used both a multivariate proportional hazard model and a propensity score matching approach to correct for sample selection bias between patients allocated or not to ASCT in intention-to-treat (ITT).Results: Among 527 patients screened from 14 centers in France, Belgium and Portugal, a final cohort of 269 patients 65 years old with PTCL-not otherwise specified (NOS) (N ¼ 78, 29%), angioimmunoblastic T-cell lymphoma (AITL) (N ¼ 123, 46%) and anaplastic lymphoma kinase-positive anaplastic large cell lymphoma (ALK-ALCL) (N ¼ 68, 25%) with partial (N ¼ 52, 19%) or complete responses (N ¼ 217, 81%) after induction was identified and information about treatment allocation was carefully collected before therapy initiation from medical records. One hundred and thirty-four patients were allocated to ASCT in ITT and 135 were not. Neither the Cox multivariate model (HR ¼ 1.02; 95% CI: 0.69-1.50 for PFS and HR ¼ 1.08; 95% CI: 0.68-1.69 for OS) nor the propensity score analysis after stringent matching for potential confounding factors (logrank P ¼ 0.90 and 0.66 for PFS and OS, respectively) found a survival advantage in favor of ASCT as a consolidation procedure for patients in response after induction. Subgroup analyses did not reveal any further difference for patients according to response status, stage disease or risk category.Conclusions: The present data do not support the use of ASCT for up-front consolidation for all patients with PTCL-NOS, AITL, or ALK-ALCL with partial or complete response after induction